Quarterly Update
25/01/2023 07:00
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230125:nRSY7342Na&default-theme=true RNS Number : 7342N RTW Venture Fund Limited 25 January 2023 LEI: 549300Q7EXQQH6KF7Z84 25 January 2023 RTW Venture Fund Limited Quarterly Update RTW Venture Fund Limited (the "Company"), the London Stock Exchange Premium Listed investment company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors is pleased to announce the Factsheet for the quarter ended 31 December 2022 is now available on the Company's website (https://www.rtwfunds.com/rtw-venture-fund-ltd/fact-sheets/) . Performance § +5.1% NAV per share uplift for the quarter ended 31 December 2022. § For the full year, the Company's NAV per share returned -10.2%, outperforming both the Russell 2000 Biotech Index (-31.3%) and the Nasdaq Biotech Index (-10.9%). Clinical developments in the quarter: § Prometheus Biosciences reported positive Phase 2 data for its antibody therapy for inflammatory diseases, suggesting a best-in-class profile. § Avidity Biosciences announced a positive clinical update on its proof-of-concept Phase 1 trial for is antibody-siRNA therapy. § Rocket Pharmaceutical presented a positive data update on its LADI clinical trial. § Rocket provided an update on its Danon program, stating that the company anticipates starting its pivotal clinical trial in H1'23. § Third Harmonic Bio announced the discontinuation of its Phase 1b study for the treatment of chronic inducible urticaria. § Cincor Pharma announced the failure of its Phase 2 trial of baxdrostat for uncontrolled hypertension study by missing statistically significant difference between its treatment and placebo arms. Commercial/financial/investment developments: § The Company announced a $2m investment in Apogee Therapeutics, which is working on developing best-in-class medicines for immunological and inflammatory diseases. RTW Investments, LP co-lead the Series B round. § Takeda announced the acquisition of Nimbus' TYK2-targeting drug, providing a positive read-through for RTW Venture Ltd.'s holding in Ventyx, which is also advancing a TYK2-targeting therapy. § After the quarter end, Cincor entered into an agreement to be acquired by AstraZeneca for a total deal value of $1.8bn, a 206% premium to the prior closing market value. For Further Information RTW Investments, LP +44 (0) 77 1741 7711 Woody Stileman, Managing Director Buchanan +44 (0)20 7466 5107 Charles Ryland Henry Wilson George Beale J.P. Morgan Cazenove +44 (0)20 7742 4000 William Simmonds Jérémie Birnbaum James Bouverat (Sales) BofA Securities +44 (0) 20 7628 1000 Edward Peel Kieran Millar Elysium Fund Management Limited +44 (0) 14 8181 0100 Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director Morgan Stanley Fund Services USA LLC +1 (914) 225 8885 About RTW Venture Fund Limited: RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund Limited invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Venture Fund Limited is managed by RTW Investments, LP, (the "Investment Manager"), a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies. Visit the RTW website at www.rtwfunds.com (https://protect.mimecast-offshore.com/s/eY8OCgLEp4SlY4JEFN_vEF) for more information. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END UPDBLGDBSDDDGXS